8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 22, 2026·SEC
Material company update
Mar 19, 2026·SEC
SAB Biotherapeutics, Inc.(SABS)Earnings, Financials & Key Ratios
SABS•NASDAQ
$3.92
Price updated Jul 6, 2026
AboutSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.Show more
- Revenue$0-100.0%
- EBITDA-$46M-20.3%
- Net Income$13M+138.9%
- EPS (Diluted)-0.79+78.5%
- ROE14.96%+118.3%
SABS Price & Volume
SAB Biotherapeutics, Inc. (SABS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Platform Asset Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity depletion
Key Thesis Takeaways
- SAB Biotherapeutics faces a critical juncture as its transition from pandemic-era government funding to a proprietary autoimmune pipeline remains unproven, evidenced by a complete cessation of commercial revenue since 2025Q1.
- The company's reliance on a specialized transchromosomic bovine herd necessitates significant R&D spending, which reached $13.4 million in 2026Q1, creating a structural disconnect between operational costs and revenue generation.
- Investors should monitor the firm's ability to secure non-dilutive capital, as the current $20.5 million cash position against a $15.3 million quarterly free cash flow burn suggests a high probability of near-term liquidity constraints.
Verdict Logic
the company's current quarterly burn rate of $15.3 million against a cash balance of $20.5 million suggests an imminent risk of liquidity depletion and potential shareholder dilution.
SABS Growth Metrics
SAB Biotherapeutics, Inc. (SABS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-7.98%
3 Years-
TTM98.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.51%
Return on Capital
10 Years-40.46%
5 Years-57.65%
3 Years-65.9%
Last Year-49.36%
SABS Recent Earnings
SAB Biotherapeutics, Inc. (SABS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 1/12 qtrs (25%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.35-75.0%
$0.20
Rev
—
$125,000
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.46-187.5%
$0.16
Rev
—
$100,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.21+64.4%
$0.59
Rev
—
$100,000
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.09-32.9%
$0.82
Rev
—
$83,330
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.35vs $0.20-75.0% | —vs $125,000 |
| Q2 2026 | Mar 9, 2026 | $0.46vs $0.16-187.5% | —vs $100,000 |
| Q4 2025 | Nov 14, 2025 | $0.21vs $0.59+64.4% | —vs $100,000 |
| Q3 2025 | Aug 7, 2025 | $1.09vs $0.82-32.9% | —vs $83,330 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for SAB Biotherapeutics, Inc. (SABS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.92 | $209.95M | -4.96 | -100% | — | 14.96% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $916.80 | $56.73B | 46.70 | 89.64% | 32.14% | 24.93% | — | |
| $80.78 | $9.58B | 31.55 | 37.55% | 23.13% | 126.27% | — | |
| $9.16 | $2.12B | 15.27 | 19.63% | 32.43% | 38.97% | — | |
| $15.17 | $1.28B | -28.62 | — | — | -38.92% | — |
Compare SABS vs Peers
SAB Biotherapeutics, Inc. (SABS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SABS SEC Filings & Documents
SAB Biotherapeutics, Inc. (SABS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SABS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SABS Frequently Asked Questions
SAB Biotherapeutics, Inc. (SABS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is SAB Biotherapeutics, Inc. growing?
SAB Biotherapeutics, Inc. (SABS) saw revenue decline by 100.0% over the past year.
Is SABS profitable?
SAB Biotherapeutics, Inc. (SABS) reported a net loss of $0.4M for fiscal year 2025.
Dividend & Returns
What is SABS's return on equity?
SAB Biotherapeutics, Inc. (SABS) has a return on equity (ROE) of 15.0%. This is reasonable for most industries.
What is SAB Biotherapeutics, Inc.'s free cash flow?
SAB Biotherapeutics, Inc. (SABS) had negative free cash flow of $53.2M in fiscal year 2025, likely due to heavy capital investments.